• Home
  • News

Jilin Pfizer Guoyuan Animal Health Company Established in China

Category:

Thursday, November 3, 2011 8:08 am EDT
"It is our pleasure to have Pfizer as our partner. We share the same vision and mission in the field of animal health. We will jointly achieve success in swine vaccines and other animal health products in China"

JILIN--Pfizer Animal Health, a business unit of Pfizer (NYSE: PFE), and Jilin Guoyuan Animal Health Co., Ltd., announced today the establishment of the joint venture Jilin Pfizer Guoyuan Animal Health Co., Ltd. The joint venture, which has been granted a license by local Chinese government authorities, formalizes the strategic agreement signed on September 8 to develop, manufacture, and distribute animal vaccines in China. Terms of the agreement were not disclosed.

The new company will focus initially on swine vaccine development and commercialization. In the future, it will consider new opportunities to offer Chinese livestock producers a comprehensive range of vaccine products to help protect the health of food production animals.

“As Chinese society is becoming more affluent, demand for meat, especially pork, is rapidly increasing. A quality, affordable food supply begins with healthy animals,” said Juan Ramón Alaix, president, Pfizer Animal Health. “We believe Jilin Pfizer Guoyuan will meet China’s livestock producers’ needs for quality vaccines to help protect the health of food production animals.”

He added that Pfizer Animal Health views China as a center for innovation. “The joint venture with Jilin Guoyuan not only demonstrates Pfizer Animal Health’s commitment to growth in China but also will help accelerate the development of China’s animal health industry,” Alaix said. “In Jilin Guoyuan we found the ideal partner with the company’s scientific expertise, a strong early to late stage vaccine development program, and a new manufacturing facility in the Huinan Economic Development Zone. We are confident that our collaboration with Jilin Guoyuan will deliver value to China’s livestock producers and the veterinarians who support them.”

“It is our pleasure to have Pfizer as our partner. We share the same vision and mission in the field of animal health. We will jointly achieve success in swine vaccines and other animal health products in China,” said Dr. Wu Hua, former General Manager of Jilin Guoyuan Animal Health Co., Ltd. “Building up the strategic partnership with Pfizer is just the first step, and Jilin Pfizer Guoyuan will further offer our resources and expand our business countrywide and overseas. In this way, both parties will make a contribution to the development of China’s animal health industry in the near future.”

China’s animal vaccines market is valued at $800 million. Vaccines for swine have high growth potential as China is the world’s leading pork producing nation, with an annual population of more than 600 million pigs. The joint venture provides a strategic platform for growth in China, a $3.4 billion1 animal health market and the second largest in the world with an expected compound annual growth rate of approximately ten percent.

About Jilin Guoyuan Animal Health Company

Jilin Guoyuan Animal Health Company was established in 2009 and has been mainly engaged in R&D, manufacturing and sales of animal health biological products. It has set up its manufacturing base in Huinan Economic Development Zone in Jilin, which includes a GMP certified production building, animal housing for quality testing, an administrative office building and other auxiliary buildings.

About Pfizer Animal Health

Pfizer Animal Health (PAH) is one of the world’s largest animal health production companies, leading the global animal health production industry. PAH provides a comprehensive range of medicines, vaccines and animal health services and works to assure that companion animals live longer, healthier lives and to assure a quality, sustainable global food supply from healthy livestock.

PAH-China has registered and launched a series of products for swine, dairy cattle, poultry and companion animals, including vaccines, antibiotics, parasiticides and disinfectants. Improvac, a novel vaccine for swine approved in September, 2010, further expanded PAH’s products in China.

Relying on strength In R&D and product line, PAH works to provide animal health solutions of high quality and efficiency, and comprehensive services of high quality, with the aim to promote the development of China husbandry.

For more information about Pfizer Animal Health, please visit https://animalhealth.pfizer.com.

Contact:

PAH Contact:
Ping Yu
Tel: 020-8384806-883
Email: ping.yu@pfizer.com